Enovis Corporation $ENOV Shares Purchased by State of Alaska Department of Revenue

State of Alaska Department of Revenue lifted its position in shares of Enovis Corporation (NYSE:ENOV) by 8.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,027 shares of the company’s stock after buying an additional 2,523 shares during the period. State of Alaska Department of Revenue owned approximately 0.06% of Enovis worth $1,066,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its stake in Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock worth $27,000 after acquiring an additional 536 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Enovis by 144.8% during the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock worth $45,000 after purchasing an additional 692 shares during the period. DekaBank Deutsche Girozentrale increased its position in Enovis by 57.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company’s stock worth $74,000 after purchasing an additional 725 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new position in Enovis in the first quarter valued at approximately $198,000. Finally, McIlrath & Eck LLC lifted its position in Enovis by 52.2% during the first quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock valued at $202,000 after buying an additional 1,808 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Price Performance

ENOV opened at $32.02 on Monday. The company has a market capitalization of $1.83 billion, a P/E ratio of -2.25 and a beta of 1.69. The company has a 50-day moving average of $30.09 and a 200-day moving average of $32.03. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25. Enovis Corporation has a 1-year low of $25.47 and a 1-year high of $49.83.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. The business had revenue of $564.50 million during the quarter, compared to the consensus estimate of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the firm earned $0.62 earnings per share. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. Equities analysts expect that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insider Transactions at Enovis

In other news, SVP Bradley J. Tandy acquired 3,200 shares of Enovis stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average cost of $31.41 per share, for a total transaction of $100,512.00. Following the completion of the purchase, the senior vice president directly owned 43,515 shares of the company’s stock, valued at $1,366,806.15. This trade represents a 7.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was acquired at an average cost of $29.71 per share, with a total value of $74,275.00. Following the acquisition, the chief financial officer owned 116,729 shares of the company’s stock, valued at $3,468,018.59. This trade represents a 2.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 12,157 shares of company stock worth $374,760. 2.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ENOV has been the subject of several recent research reports. Wells Fargo & Company dropped their price objective on shares of Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a research report on Friday, August 8th. Canaccord Genuity Group lowered their price target on Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a research note on Saturday, September 27th. Needham & Company LLC lowered their target price on Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Finally, Evercore ISI dropped their target price on Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $51.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.